| GATAD2A | |
|---|---|
| GATA Zinc Finger Domain Containing 2A | |
| Symbol | GATAD2A |
| Chromosome | 19p13.2 |
| NCBI Gene ID | 54898 |
| OMIM | 607336 |
| Ensembl ID | ENSG00000176165 |
| UniProt | Q9ULJ8 |
| Associated Diseases | Parkinson's Disease (risk factor) |
GATAD2A (GATA Zinc Finger Domain Containing 2A) is a transcriptional repressor protein and core component of the NuRD (Nucleosome Remodeling Deacetylase) complex. It is implicated in Parkinson's disease risk through genome-wide association studies (GWAS) and plays critical roles in chromatin remodeling, gene regulation, and neuronal survival. [1]
| Attribute | Value |
|---|---|
| Symbol | GATAD2A |
| Full Name | GATA Zinc Finger Domain Containing 2A |
| Chromosome | 19p13.2 |
| NCBI Gene ID | 54898 |
| OMIM | 607336 |
| Ensembl ID | ENSG00000176165 |
| UniProt | Q9ULJ8 |
| Protein Length | 593 amino acids |
GATAD2A plays critical roles in gene regulation through its involvement in the NuRD complex:
GATAD2A serves as a scaffold protein that brings together multiple enzymatic activities within the NuRD complex:
The NuRD complex represses gene transcription through multiple coordinated mechanisms [2]:
The GATA-type zinc fingers (Cys-X2-Cys-X16-Cys-X2-Cys motif) mediate:
GATAD2A has been identified as a genetic risk factor for Parkinson's disease through GWAS [3]. The mechanism involves multiple pathways:
GATAD2A may regulate alpha-synuclein (SNCA) expression through:
GATAD2A is widely expressed in human tissues:
GATAD2A represents a potential therapeutic target through:
Lauberth et al. Chromatin programming by ZFP57 and GATAD2A in epigenetic memory. Nature. 2013. ↩︎
Millar et al. NuRD-deficiencies in neurological disease. Front Neurosci. 2014. ↩︎
Nalls MA et al. Identification of novel Parkinson's disease loci. Nat Genet. 2019. ↩︎